Recursion Pharmaceuticals (RXRX) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tarsus Pharmaceuticals (TARS) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 7.6% versus a loss of 18.4%. Over five years, TARS leads with a +158.1% price change compared with -77.6% for RXRX. Tarsus Pharmaceuticals is the larger company by market cap ($3.39 billion vs $2.10 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RXRX | TARS |
|---|---|---|
| Share price | $3.91 | $72.52 |
| Market cap | $2.10B | $3.39B |
| 1-day change | -8.41% | -1.49% |
| YTD return | +4.40% | -10.10% |
| 1-year return | -18.36% | +7.59% |
| 5-year return | -77.57% | +158.10% |
| EPS (TTM) | $-1.00 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.36M |
| Revenue growth (YoY) | — | +146.71% |
| Net income (latest FY) | — | $-66.42M |
| Operating margin | — | -15.72% |
| Net margin | — | -14.72% |
| 52-week high | $7.18 | $91.53 |
| 52-week low | $2.77 | $53.89 |
| Distance from 52-week high | -45.53% | -20.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +84.61% | +37.21% |
| Average volume | 20.56M | 894.35K |
| Shares outstanding | 535.34M | 46.79M |
| Employees | 600 | 370 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARS has outperformed RXRX by 25.9 percentage points over the past year.
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 370 employees
RXRX vs TARS FAQ
Which is bigger, Recursion Pharmaceuticals or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.39B compared with $2.10B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, RXRX or TARS?
TARS returned +7.59% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Recursion Pharmaceuticals and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.